← Back to all substances
N

venlafaxine

134ms
Level 1

✓ What this shows

  • • Reported adverse events from FDA FAERS
  • • Descriptive statistics from a locked corpus
  • • Data verified with cryptographic hashes

✗ What this is NOT

  • • Not medical advice or recommendations
  • • Not proof of causality
  • • Not a complete safety profile

About this substance

INDICATIONS AND USAGE Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6 week controlled trials of adult outpatients whose diagnoses corresponded most close...

Known as: Venlafaxine
Route: ORAL
Source: OpenFDA Drug Labels · Reference only · Not medical advice
500
Events in Corpus
v20260131-01
87,333
Total in FDA
77%
Serious Reports
80
Fatal Outcomes

Seriousness

Serious
387
Non-Serious
113

Sex Distribution

Male
153
Female
328
Unknown
19

Age Distribution

0-17
19
18-40
73
41-64
199
65-84
81
85+
8
Unknown
120

Outcomes

Recovered/Resolved
329
Recovering/Resolving
122
Not Recovered/Not Resolved
267
Recovered with Sequelae
22
Fatal
80
Unknown
827

Top Reported Reactions (click to view reports)

Verification Data

Corpus Version: v20260131-01
Root Hash: ec5727564d1ed19be5b08b26d3866f446b12d3d388f5a8cd713332c6d97ad264
Stats Hash: N/A
EVE Decision ID: EVE-MED-20260402-2b6434
ℹThis output reports adverse events from FDA FAERS. It does not constitute medical advice.

Molecular Structure (reference)

Structural visualization for identification only.

This visualization shows the molecular structure for identification purposes only. It does not represent pharmacological effect, safety, or clinical relevance.

Loading structure...